Experimental Blood Test Detects High-Risk Precancerous Colon Lesions Before Cancer Develops
What's Happening
Researchers have developed an experimental blood test that can detect not only colorectal cancer but also advanced precancerous colon lesions, potentially allowing doctors to prevent cancer before it develops.
In a study involving more than 1,500 adults participating in colonoscopy screening programs in China, Japan, and Spain, the blood test detected 92% of stage I–III colorectal cancers and 81% of advanced adenomas—high-risk precancerous polyps that can be removed before they become cancerous. The findings were published in The Lancet Gastroenterology & Hepatology.
Unlike currently available blood-based screening tests, the new test is designed to identify patients with advanced adenomas, making it a potential tool for cancer prevention, not just cancer detection.
Why the Test Is Different
Most existing blood tests focus on detecting colorectal cancer after it has already developed. The new blood test can also identify advanced adenomas, which are large or high-risk precancerous polyps that can be removed during colonoscopy before they progress to cancer.
Study results showed the test:
- Detected 92% of stage I–III colorectal cancers.
- Detected 81% of advanced adenomas.
- Correctly identified 85% of people who did not have advanced precancerous lesions.
Researchers also found the test could distinguish between low-risk adenomas, high-risk adenomas, and established colorectal cancers, which may help physicians prioritize patients who need the most urgent colonoscopy.
Potential Benefits
A blood-based screening option could improve colorectal cancer prevention by increasing participation among people who avoid colonoscopy because of bowel preparation, discomfort, or inconvenience. Researchers believe the test could help:
- Identify patients who need immediate colonoscopy.
- Detect precancerous lesions before cancer develops.
- Reduce unnecessary colonoscopies for lower-risk patients.
- Improve screening participation through a less invasive option.
However, researchers emphasized that colonoscopy remains the gold standard because it both detects and removes precancerous polyps during the same procedure. Positive blood test results would still require follow-up colonoscopy.
Industry Impact
- Patients: A simple blood test could encourage more people to undergo colorectal cancer screening, particularly those reluctant to have a colonoscopy.
- Healthcare Providers: Primary care physicians and gastroenterologists may eventually have another screening tool to help identify patients who should undergo diagnostic colonoscopy.
- Diagnostic Companies: The study reflects continued innovation in non-invasive cancer screening technologies aimed at improving early detection and prevention.
- Public Health: Higher screening rates could reduce colorectal cancer incidence by identifying and removing precancerous lesions before they become malignant.
Looking Ahead
Researchers say larger clinical trials are needed before the test can be considered for widespread clinical use. They also noted that while the assay performed well for advanced adenomas, it was less accurate at detecting flat (sessile) precancerous lesions, an area that requires further improvement.
Why This Matters
Colorectal cancer is one of the leading causes of cancer-related deaths, yet it is also one of the most preventable cancers when precancerous polyps are detected and removed early. A blood test capable of identifying high-risk precancerous lesions could complement existing screening methods and help prevent cancer rather than simply detecting it after it has developed.
Key Takeaways
- Researchers developed an experimental blood test that detects both colorectal cancer and advanced precancerous colon lesions.
- The test detected 92% of stage I–III colorectal cancers and 81% of advanced adenomas.
- It may help identify patients who need urgent colonoscopy while reducing unnecessary procedures for lower-risk individuals.
- Colonoscopy remains the preferred screening method and is still required after a positive blood test.
- Larger studies are needed before the test can become part of routine clinical practice.
What This Means for Healthcare Marketers
The study highlights continued innovation in cancer screening, molecular diagnostics, and preventive oncology. Diagnostic companies, health systems, gastroenterology practices, and cancer screening programs continue investing in less invasive technologies that can improve screening participation and detect disease earlier. For healthcare marketers, organizations involved in oncology, diagnostics, laboratory medicine, preventive care, and population health represent high-intent opportunities for provider education, scientific communications, and screening awareness initiatives.